Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F13%3A43907345" target="_blank" >RIV/00216208:11120/13:43907345 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00064173:_____/13:N0000001
Výsledek na webu
<a href="http://dx.doi.org/10.1136/heartjnl-2012-303368" target="_blank" >http://dx.doi.org/10.1136/heartjnl-2012-303368</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1136/heartjnl-2012-303368" target="_blank" >10.1136/heartjnl-2012-303368</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program
Popis výsledku v původním jazyce
Overlapping first generation sirolimus- and paclitaxel-eluting stents are associated with persistent inflammation, fibrin deposition and delayed endothelialisation in preclinical models, and adverse angiographic and clinical outcomes-including death andmyocardial infarction (MI)-in clinical studies. To establish as to whether there are any safety concerns with newer generation drug-eluting stents (DES). Propensity score adjustment of baseline anatomical and clinical characteristics were used to compareclinical outcomes (Kaplan-Meier estimates) between patients implanted with overlapping DES (Resolute zotarolimus-eluting stent (R-ZES) or R-ZES/other DES) against no overlapping DES. Additionally, angiographic outcomes for overlapping R-ZES and everolimus-eluting stents were evaluated in the randomised RESOLUTE All-Comers Trial. Patient level data from five controlled studies of the RESOLUTE Global Clinical Program evaluating the R-ZES were pooled. Enrolment criteria were generally unre
Název v anglickém jazyce
Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program
Popis výsledku anglicky
Overlapping first generation sirolimus- and paclitaxel-eluting stents are associated with persistent inflammation, fibrin deposition and delayed endothelialisation in preclinical models, and adverse angiographic and clinical outcomes-including death andmyocardial infarction (MI)-in clinical studies. To establish as to whether there are any safety concerns with newer generation drug-eluting stents (DES). Propensity score adjustment of baseline anatomical and clinical characteristics were used to compareclinical outcomes (Kaplan-Meier estimates) between patients implanted with overlapping DES (Resolute zotarolimus-eluting stent (R-ZES) or R-ZES/other DES) against no overlapping DES. Additionally, angiographic outcomes for overlapping R-ZES and everolimus-eluting stents were evaluated in the randomised RESOLUTE All-Comers Trial. Patient level data from five controlled studies of the RESOLUTE Global Clinical Program evaluating the R-ZES were pooled. Enrolment criteria were generally unre
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FA - Kardiovaskulární nemoci včetně kardiochirurgie
OECD FORD obor
—
Návaznosti výsledku
Projekt
—
Návaznosti
N - Vyzkumna aktivita podporovana z neverejnych zdroju
Ostatní
Rok uplatnění
2013
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Heart
ISSN
1355-6037
e-ISSN
—
Svazek periodika
99
Číslo periodika v rámci svazku
9
Stát vydavatele periodika
GB - Spojené království Velké Británie a Severního Irska
Počet stran výsledku
8
Strana od-do
626-633
Kód UT WoS článku
000317110400007
EID výsledku v databázi Scopus
—